

**CENTRAL PHARMACEUTICAL JOINT  
STOCK COMPANY NO 2**  
NO:        /

*(Issued according to the ministry of finance's  
circular No. 200/2014/TT-BTC dated  
December 22nd, 2014)*

# **FINANCIAL STATEMENTS**

## **FIRST QUARTER 2025**

Balance Sheet	Form: B01-DN
Income Statement	Form: B02-DN
Cash Flow Statement	Form: B03-DN
Notes to the financial statement	Form: B09-DN

*Recipient: .....*

## CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Address: No. 9 Tran Thanh Tong Street, Bach Dang Ward,  
Hai Ba Trung District, Hanoi

## FINANCIAL STATEMENTS

Form B 01 - DN

## BALANCE SHEET

First Quarter

Unit: VND

ASSETS	Codes	Notes	31/03/2025	01/01/2025
<b>A. CURRENT ASSETS</b>	<b>100</b>		<b>131,253,809,538</b>	<b>129,841,539,917</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>		<b>2,780,100,239</b>	<b>5,053,168,373</b>
1. Cash	111	V.1.	2,780,100,239	5,053,168,373
<b>II. Short-term financial investments</b>	<b>120</b>		-	-
<b>III. Short-term receivables</b>	<b>130</b>		<b>79,756,252,270</b>	<b>76,690,595,733</b>
1. Short-term trade accounts receivable	131	V.3.	26,033,104,570	22,152,834,582
2. Advances to suppliers	132	V.4.	1,426,421,061	913,567,035
3. Other short-term receivables	136	V.5.	56,908,210,834	58,235,678,311
4. Allowances for short-term doubtful debts	137	V.6.	(4,611,484,195)	(4,611,484,195)
<b>IV. Inventories</b>	<b>140</b>	<b>V.7.</b>	<b>48,331,029,091</b>	<b>47,610,369,449</b>
1. Inventories	141		48,331,029,091	47,610,369,449
2. Allowances for inventories	149		-	-
<b>V. Other short-term assets</b>	<b>150</b>		<b>386,427,938</b>	<b>487,406,362</b>
1. Short-term prepayments	151	V.11.	205,475,386	160,618,558
2. Deductible VAT	152		108,515,326	257,777,679
3. Taxes and other receivables from the State budget	153	V.14.	72,437,226	69,010,125
<b>B. NON-CURRENT ASSETS</b>	<b>200</b>		<b>307,151,795,939</b>	<b>312,791,806,940</b>
<b>I. Long-term receivables</b>	<b>210</b>		<b>72,240,000,000</b>	<b>72,240,000,000</b>
1. Other long-term receivables	216	V.5.	72,240,000,000	72,240,000,000
<b>II. Fixed assets</b>	<b>220</b>		<b>126,705,405,448</b>	<b>132,236,602,153</b>
1. Tangible fixed assets	221	V.10.	126,705,405,448	132,236,602,153
- Historical cost	222		289,655,763,230	289,655,763,230
- Accumulated depreciation	223		(162,950,357,782)	(157,419,161,077)
2. Intangible fixed assets	227	V.8.	-	-
- Historical cost	228		810,751,750	810,751,750
- Accumulated amortization	229		(810,751,750)	(810,751,750)
<b>III. Investment property</b>	<b>230</b>		-	-
<b>IV. Long-term assets in progress</b>	<b>240</b>		<b>76,805,661</b>	<b>76,805,661</b>
1. Construction in progress	242	V.9.	76,805,661	76,805,661
<b>V. Long-term financial investments</b>	<b>250</b>		<b>93,960,000,000</b>	<b>93,960,000,000</b>
1. Equity investments in other entities	253	V.2.	93,960,000,000	93,960,000,000
<b>VI. Other long-term assets</b>	<b>260</b>		<b>14,169,584,830</b>	<b>14,278,399,126</b>
1. Long-term prepayments	261	V.11.	14,169,584,830	14,278,399,126

<b>TOTAL ASSETS (270=100+200)</b>	<b>270</b>	<b>438,405,605,477</b>	<b>442,633,346,857</b>
-----------------------------------	------------	------------------------	------------------------

Unit: VND

RESOURCES	Codes	Notes	31/03/2025	01/01/2025
<b>C LIABILITIES</b>	<b>300</b>		<b>360,885,603,827</b>	<b>361,660,487,896</b>
<b>I. Current liabilities</b>	<b>310</b>		<b>266,925,603,827</b>	<b>267,700,487,896</b>
1. Short-term trade accounts payable	311	V.12.	23,249,272,211	19,658,618,096
2. Short-term advances from customers	312	V.13.	15,564,986,589	18,990,940,376
3. Taxes and amounts payable to the State budget	313	V.14.	53,995,905,662	54,006,314,179
4. Payables to employees	314		1,617,231,104	3,332,236,406
5. Short-term accrued expenses	315	V.15.	41,191,171,141	38,669,880,463
6. Other short-term payables	319	V.17.	28,926,405,034	30,861,866,290
7. Short-term loans and obligations under finance leases	320	V.16.	102,095,578,312	101,895,578,312
8. Bonus and welfare funds	322		285,053,774	285,053,774
<b>II. Long-term liabilities</b>	<b>330</b>		<b>93,960,000,000</b>	<b>93,960,000,000</b>
1. Other long-term payables	337	V.17.	93,960,000,000	93,960,000,000
2. Long-term loans and obligations under finance leases	338	V.16.	-	-
<b>D EQUITY</b>	<b>400</b>		<b>77,520,001,650</b>	<b>80,972,858,961</b>
<b>I. Owner's equity</b>	<b>410</b>	<b>V.18.</b>	<b>77,344,711,650</b>	<b>80,797,568,961</b>
1. Owner's contributed capital	411		200,000,000,000	200,000,000,000
- <i>Ordinary shares carrying voting rights</i>	411a		200,000,000,000	200,000,000,000
2. Share premium	412		4,902,500,000	4,902,500,000
3. Investment and development fund	418		3,267,017,189	3,267,017,189
4. Other reserves	420		249,948,734	249,948,734
5. Retained earnings	421		(131,074,754,273)	(127,621,896,962)
Retained earnings accumulated to the prior year end	421a		(127,621,896,962)	(122,067,787,967)
Retained earnings of current year	421b		(3,452,857,311)	(5,554,108,995)
<b>II. Other resources and funds</b>	<b>430</b>		<b>175,290,000</b>	<b>175,290,000</b>
1. Subsidised funds	431		175,290,000	175,290,000
<b>TOTAL RESOURCES (440=300+400)</b>	<b>440</b>		<b>438,405,605,477</b>	<b>442,633,346,857</b>

Ha Noi, 15 April, 2025

**CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2**

Prepared by

Chief Accountant

General Director

Dinh Thi Minh Huong

Nguyen Thi Dieu Thuy



Le Tien Dung



Address: No. 9 Tran Thanh Tong Street,  
Bach Dang Ward, Hai Ba Trung District,  
Hanoi

Form B 02 - DN

## INCOME STATEMENT

First Quarter

Unit: VND

	Items	Codes	Notes	Current quarter	Same quarter previous year	Cumulative figure from the beginning of current year to the end of current quarter	Cumulative figure from the beginning of the previous year to the end of the same quarter previous year
1.	Gross revenue from goods sold and services rendered	01	VI.1.	41,509,407,053	44,854,908,983	41,509,407,053	44,854,908,983
2.	Deductions	02	VI.2.	-	-	-	-
3.	Net revenue from goods sold and services rendered (10=01-02)	10		41,509,407,053	44,854,908,983	41,509,407,053	44,854,908,983
4.	Cost of sales	11	VI.3.	38,584,533,087	41,009,841,285	38,584,533,087	41,009,841,285
5.	Gross profit from goods sold and services rendered (20=10-11)	20		2,924,873,966	3,845,067,698	2,924,873,966	3,845,067,698
6.	Financial income	21	VI.4.	4,937,658	1,061,811	4,937,658	1,061,811
7.	Financial expenses	22	VI.5.	2,788,326,272	2,782,080,724	2,788,326,272	2,782,080,724
	In which: Interest expense	23		2,778,025,172	2,727,034,967	2,778,025,172	2,727,034,967
8.	Selling expenses	25	VI.8.	779,466,057	704,173,323	779,466,057	704,173,323
9.	General and administration expenses	26	VI.8.	2,839,647,444	3,845,746,561	2,839,647,444	2,877,491,906
10.	Operating profit {30=20+(21-22)+24-(25+26)}	30		(3,477,628,149)	(2,517,616,444)	(3,477,628,149)	(2,517,616,444)
11.	Other income	31	VI.6.	53,352,991	1,156,421,501	53,352,991	1,156,421,501
12.	Other expenses	32	VI.7.	28,582,153	32,881,973	28,582,153	32,881,973
13.	Profit from other activities (40=31-32)	40		24,770,838	1,123,539,528	24,770,838	1,123,539,528
14.	Accounting profit before tax (50=30+40)	50		(3,452,857,311)	(1,394,076,916)	(3,452,857,311)	(1,394,076,916)
15.	Current corporate income tax expense	51	VI.9.	-	-	-	-
16.	Net profit after corporate income tax (60=50-51-52)	60		(3,452,857,311)	(1,394,076,916)	(3,452,857,311)	(1,394,076,916)
17.	Basic earning per share	70	VI.11.	-	-	-	-

Ha Noi, 15 April, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director





Dinh Thi Minh Huong

Nguyen Thi Dieu Thuy

Le Tien Dung

Form B 03 - DN

**CASH FLOW STATEMENT***First Quarter*

Unit: VND

Items		Codes	Notes	Cumulative figure from the beginning of current year to the end of current quarter	Cumulative figure from the beginning of the previous year to the end of the same quarter previous year
<b>I.</b>	<b>Cash flow from operating activities</b>				
1.	Revenue from sales and services and other income	01		34,499,985,984	30,301,912,421
2.	Payments to suppliers of goods and services	02		(26,983,911,511)	(22,462,650,213)
3.	Cash paid to employees	03		(6,707,150,175)	(5,781,143,623)
4.	Paid loan interest	04		(849,320,000)	(603,839,363)
5.	Paid corporate income tax	05		-	-
6.	Other cash inflows from operating activities	06		3,567,184,146	3,452,065,211
7.	Other cash outflows from operating activities	07		(5,999,856,578)	(6,350,553,139)
<b>Net cash flow used in operating activities</b>		<b>20</b>		<b>(2,473,068,134)</b>	<b>(1,444,208,706)</b>
<b>II.</b>	<b>Cash flow from investing activities</b>				
1.	Acquisition and construction of fixed assets and other non-current assets	21		-	-
2.	Interest earned, dividends and received profits	27		-	-
<b>Net cash flow used in investing activities</b>		<b>30</b>		<b>-</b>	<b>-</b>
<b>III.</b>	<b>Cash flow from financing activities</b>				
1.	Proceeds from borrowing	33		200,000,000	250,000,000
2.	Prepayment of borrowing	34		-	-
3.	Dividends and profits paid to owners	36		-	-
<b>Net cash flow from financing activities</b>		<b>40</b>		<b>200,000,000</b>	<b>250,000,000</b>



Net increase/decrease in cash (50 = 20+30+40)	50		(2,273,068,134)	(1,194,208,706)
Cash and cash equivalents at the beginning of the year	60		5,053,168,373	3,584,348,015
Effect of changes in foreign exchange rates	61		-	-
Cash and cash equivalents at the end of the year (70 = 50+60+61)	70	V.1	2,780,100,239	2,390,139,309

Hà Nội, 15 April, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung





**NOTES TO THE FINANCIAL STATEMENTS***(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)***I. Additional information for items presented in the Balance Sheet**

1. Cash	31/03/2025	01/01/2025
	VND	VND
Cash on hand	486,643,760	594,457,069
Cash in bank	2,293,456,479	4,458,711,304
<b>Total</b>	<b>2,780,100,239</b>	<b>5,053,168,373</b>

**2. Financial investments***Investments in other entities*

	31/03/2025		01/01/2025	
	VND		VND	
	Historical cost	Provision	Historical cost	Provision
<i>Long-term</i>				
Binh An Developed Investment Joint Stock Company (i)	93,960,000,000	-	93,960,000,000	-
<b>Total</b>	<b>93,960,000,000</b>	<b>-</b>	<b>93,960,000,000</b>	<b>-</b>

**3. Trade receivables**

	31/03/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
<i>Short-term</i>				
	-	-	-	-
Central Pharmaceutical CPCI. JSC				
Vinh Quang Independent Pharmacy	1,032,951,634	-	1,179,863,634	-
Tam Phat Pharmaceutical Trading JSC	4,658,016,208	-	2,431,803,708	-
Huong Viet Pharmaceutical JSC	2,273,510,179	-	2,361,553,219	-
Sapphire Pharmaceutical Co., Ltd	1,048,414,352	-	1,048,414,352	-
Others	17,020,212,197		15,131,199,669	
<b>Total</b>	<b>26,033,104,570</b>	<b>-</b>	<b>22,152,834,582</b>	<b>-</b>

**4. Advances to suppliers**

	31/03/2025	01/01/2025
	VND	VND

## NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

National Institute of Drug Quality Control	-	-
Viet Nam Auditing & Evaluation Company Limited	35,000,000	35,000,000
Consulting designing an investment service joint stock company	-	-
Others	1,391,421,061	878,567,035
<b>Total</b>	<b>1,426,421,061</b>	<b>913,567,035</b>

## 5. Other receivables

	31/03/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
<b>a) Short-term</b>	<b>56,285,914,137</b>	<b>-</b>	<b>56,282,455,889</b>	
Advances	151,917,426		166,917,426	
Mortgages, collaterals	1,019,143,796	-	937,656,060	
Social insurance paid for	-	-	-	
Other receivables	55,114,852,915	-	55,177,882,403	
<i>Binh An Developed Investment JSC (i)</i>	<i>49,600,314,938</i>	<i>-</i>	<i>49,600,314,938</i>	
<i>Tran Bao Cuong</i>	<i>2,320,000,000</i>	<i>-</i>	<i>2,320,000,000</i>	
<i>Others</i>	<i>3,194,537,977</i>	<i>-</i>	<i>3,257,567,465</i>	
<b>b) Long-term</b>	<b>72,240,000,000</b>	<b>-</b>	<b>72,240,000,000</b>	<b>-</b>
Other receivables	72,240,000,000	-	72,240,000,000	-
<i>Nhat Minh Production Company Limited (ii)</i>	<i>72,240,000,000</i>	<i>-</i>	<i>72,240,000,000</i>	<i>-</i>
<b>Total</b>	<b>128,525,914,137</b>	<b>-</b>	<b>128,522,455,889</b>	<b>-</b>

## 6 Inventories

	31/03/2025		01/01/2025	
	VND		VND	
	Cost	Provision	Cost	Provision
Raw material	29,252,345,080	-	27,393,596,296	-
Tools and supplies	54,028,683	-	9,118,366	-
Work in progress	10,773,144,843	-	6,376,772,136	-
Finished goods	8,251,510,485	-	13,830,882,651	-
<b>Total</b>	<b>48,331,029,091</b>	<b>-</b>	<b>47,610,369,449</b>	<b>-</b>

## 7. Construction in progress



**NOTES TO THE FINANCIAL STATEMENTS***(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

	31/03/2025 VND	01/01/2025 VND
Cao Xoa production line project	-	1,835,035,444
Vinh Tuy complex building	76,805,661	76,805,661
<b>Total</b>	<b>76,805,661</b>	<b>1,911,841,105</b>

**8. Trade payables**

	31/03/2025 VND		01/01/2025 VND	
	Historical cost	Amount payable	Historical cost	Amount payable
<i>Short-term</i>				
VCP.,JSC	-	-	-	-
Van Son International Economic and Technical Cooperation	7,346,050,277	7,346,050,277	7,346,050,277	7,346,050,277
MI Pharma Private Limited	2,159,462,950	2,159,462,950	2,159,462,950	2,159,462,950
Aristopharma LTD	-	-	-	-
Others	13,743,758,984	13,743,758,984	10,153,104,869	10,153,104,869
<b>Total</b>	<b>23,249,272,211</b>	<b>23,249,272,211</b>	<b>19,658,618,096</b>	<b>19,658,618,096</b>

**9. Advances from customers**

	31/03/2025 VND	01/01/2025 VND
<i>Short-term</i>		
Generic Phamaceutical JSC	-	973,530,932
Southeast Asia Pharmaceutical and Medical Equipment JSC	4,338,672,323	1,518,956,641
Eastern Europe Pharmaceutical JSC	-	-
Xuan Anh Pharmaceutical and Equipment Company Limited	4,532,284,720	6,966,231,329
Sinh Phuc Pharmaceutical Technology and Trading Company Limited	-	-
Capital Pharmacy.,JSC	865,458,091	1,374,059,046
Ha Minh Technology and Trading Company Limited	-	-
Hung Viet trading and Pharmaceutical JSC	570,334,741	1,205,443,823
Others	5,258,236,714	6,952,718,605
<b>Total</b>	<b>15,564,986,589</b>	<b>18,990,940,376</b>

**10. Other payables**

**NOTES TO THE FINANCIAL STATEMENTS***(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

	31/03/2025	01/01/2025
	VND	VND
<b>a) Short-term</b>	<b>28,926,405,034</b>	<b>30,861,866,290</b>
Trade Union Fee	1,190,715,925	1,345,941,665
Other payables	27,735,689,109	29,515,924,625
Nhat Minh Production Company Limited Branch in Hanoi (i)	26,410,000,000	26,410,000,000
Others	1,325,689,109	3,105,924,625
<b>b) Long-term</b>	<b>93,960,000,000</b>	<b>93,960,000,000</b>
Other payables	93,960,000,000	93,960,000,000
Binh An Developed Investment Joint Stock Company (ii)	93,960,000,000	93,960,000,000
<b>Total</b>	<b>122,886,405,034</b>	<b>124,821,866,290</b>

**11. Owner's equity***Details of owner's equity contribution*

	31/03/2025	01/01/2025
	VND	VND
Vietnam Pharmaceutical Corporation - JSC	13,566,500,000	13,566,500,000
Viet Land Corporation	24,748,000,000	24,748,000,000
Saigon Handicraft Fine Art Export Joint Stock Company	150,000,000,000	150,000,000,000
Other shareholders	11,685,500,000	11,685,500,000
<b>Total</b>	<b>200,000,000,000</b>	<b>200,000,000,000</b>

**II. Additional information for items presented in the Income Statement****1. Gross revenue from goods sold and services rendered**

	Q1/2025	Q1/2024
	VND	VND
<b>Revenue</b>		
Revenue from sales of goods	-	-
Revenue from sales of finished products	41,509,407,053	44,854,908,983
<b>Total</b>	<b>41,509,407,053</b>	<b>44,854,908,983</b>

**2. Revenue deductions**

	Q1/2025	Q1/2024
	VND	VND
Sales Returns	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**NOTES TO THE FINANCIAL STATEMENTS***(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)***3. Cost of sales**

	Q1/2025 VND	Q1/2024 VND
Cost of goods sold	-	-
Cost of finished goods sold	38,584,533,087	41,009,841,285
<b>Total</b>	<b>38,584,533,087</b>	<b>41,009,841,285</b>

**4. Financial income**

	Q1/2025 VND	Q1/2024 VND
Interest on bank deposits and margin interest	6,733,600	2,790,665
Exchange rate difference interest arises during the year	21,543,400	1,766,429
<b>Total</b>	<b>28,277,000</b>	<b>4,557,094</b>

**5. Financial expenses**

	Q1/2025 VND	Q1/2024 VND
Interest expense	2,778,025,172	2,727,034,967
Interest on late payment	-	36,377,757
Exchange rate difference loss arising during the year	10,301,100	18,668,000
Loss from exchange rate difference due to revaluation at the year end	-	-
<b>Total</b>	<b>2,788,326,272</b>	<b>2,782,080,724</b>

**6. Other income**

	Q1/2025 VND	Q1/2024 VND
Income from warehouse leasing	13,352,180	1,096,418,350
Income from liabilities that are not payable	-	-
Other	40,000,811	60,003,151
<b>Total</b>	<b>53,352,991</b>	<b>1,156,421,501</b>

**7. Other expenses**

	Q1/2025 VND	Q1/2024 VND
Administrative fines and late payment of taxes and insurance	-	3,500,000
Inventory processing	-	-
Other	28,582,153	29,381,973
<b>Total</b>	<b>28,582,153</b>	<b>32,881,973</b>



**CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2**

Address: No. 9 Tran Thanh Tong Street, Bach Dang  
Ward, Hai Ba Trung District, Hanoi

**FINANCIAL STATEMENTS**

*First Quarter*

**Form B 09 - DN**

**NOTES TO THE FINANCIAL STATEMENTS**

*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

Ha Noi, <sup>15</sup>April, 2025

**CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2**

**Prepared by**



**Dinh Thi Minh Huong**

**Chief Accountant**



**Nguyen Thi Dieu Thuy**

**General Director**



**Le Tien Dung**

T.C.P. 10/11

CENTRAL PHARMACEUTICAL  
JOINT STOCK COMPANY NO2SOCIALIST REPUBLIC OF VIETNAM  
Independence – Freedom – Happiness

No.: 86 /CBTT-DPTU2

Hanoi, April 15, 2025

## PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS

To: Hanoi Stock Exchange

Pursuant to the provisions of Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding disclosures on the stock market, Central Pharmaceutical Joint Stock Company No2 shall disclose information on the financial statements (FS) for the first quarter 2025 to the Hanoi Stock Exchange as follows:

## 1. Company name:

- Ticker symbol: DP2
- Address: No. 9 Tran Thanh Tong Street, Bach Dang Ward, Hai Ba Trung District, Hanoi.
- Tel: 024 39716579/91: Fax: 024 35251484.
- Email: dopharma@dopharma.com.vn.
- Website: www.dopharma.com.vn \_ dopharma.vn

## 2. Disclosures:

- Financial statements for the 1st quarter of 2025

☒ Separate financial statements (The listed company has no subsidiaries and the superior accounting entity has affiliates);

☐ Consolidated financial statements (the listed company has subsidiaries);

☐ Combined financial statements (the listed company has affiliated accounting entities with separate accounting apparatus).

- Cases that require explanation:

+ The auditors gave an opinion that was not an unqualified opinion on the financial statements (for audited financial statements in 2024):

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ The difference between pre- and post-audit profit in the reporting period is 5% or more, transferring from loss to profit or vice versa (for audited financial statements in 2024):



☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

+ Profit after corporate income tax in the income statement of the reporting period changes by 10% or more compared to the same reporting period of the previous year:

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ Profit after tax in the reporting period is a loss, transferring from profit in the same period of the previous year to loss in this period or vice versa:

☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

This information was published on the Company's website on: April 18, 2025: [www.dopharma.com.vn](http://www.dopharma.com.vn) \_ [dopharma.vn](http://dopharma.vn)

**Attachments:**

- Financial statements for the first quarter of 2025
- Explanation of financial statements for the first quarter

**For the Company**  
Legal representative/ person authorized to make disclosures  
(Signature, full name, position, seal)



**Pharmacist Le Tien Dung**

